Gefurulimab found to ease gMG symptoms in global Phase 3 trial
Gefurulimab outperformed a placebo in easing gMG symptoms in a clinical trial involving over 250 patients positive for anti-AChR antibodies.| Myasthenia Gravis News
Gefurulimab outperformed a placebo in easing gMG symptoms in a clinical trial involving over 250 patients positive for anti-AChR antibodies.| Myasthenia Gravis News
Zilbrysq was found safe and effective in a clinical trial for generalized myasthenia gravis patients who switched from other C5 inhibitors.| Myasthenia Gravis News
The FDA has approved once-daily zilucoplan as Zilbrysq for adults with generalized MG who are positive for antibodies targeting AChR.| Myasthenia Gravis News
No description.| Myasthenia Gravis News
Soliris effectively eased symptoms and reduced the need for other medications in adults with MG in a clinical practice setting, data show.| Myasthenia Gravis News
Myasthenia gravis is a neuromuscular disease characterized by weakness and fatigue that can affect muscles involved in voluntary movements.| Myasthenia Gravis News
